PSNL logo

PSNL
Personalis Inc

2,788
Mkt Cap
$863.95M
Volume
2.69M
52W High
$11.50
52W Low
$3.84
PE Ratio
-8.33
PSNL Fundamentals
Price
$8.47
Prev Close
$8.25
Open
$8.35
50D MA
$6.53
Beta
2.17
Avg. Volume
1.83M
EPS (Annual)
-$0.9107
P/B
3.48
Rev/Employee
$267,876.92
$511.21
Loading...
Loading...
News
all
press releases
US Agency Broadens Coverage Of Personalis Breast Cancer Test
Personalis wins expanded Medicare coverage for NeXT Personal MRD test in breast cancer patients undergoing neoadjuvant therapy.read more...
News Placeholder
More News
News Placeholder
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the companys NeXT Personal minimal residual disease (MRD) test. The...
News Placeholder
Personalis to Participate in Upcoming Investor Events
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: Craig Hallum...
News Placeholder
Personalis Receives Medicare Coverage for NeXT Personal for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program...
News Placeholder
Personalis (PSNL) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
News Placeholder
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of -26.09% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Personalis Reports First Quarter Results and Recent Highlights
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the first quarter ended March 31, 2026, highlighted recent...
News Placeholder
Personalis, Inc. $PSNL Shares Sold by AIGH Capital Management LLC
AIGH Capital Management LLC lowered its position in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 25.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,900,000 shares of the company's stock after se...
News Placeholder
Personalis (NASDAQ:PSNL) Stock Price Up 12.5% - Still a Buy?
Personalis (NASDAQ:PSNL) Shares Up 12.5% - Here's Why...
News Placeholder
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven ratings firms that are covering the firm, MarketBeat.com reports. One...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available